Effects of tranexamic acid and bipolar sealer alone or in combination in primary total knee arthroplasty: a prospective, randomized, controlled trial  by Seviciu, Alexandru et al.
lable at ScienceDirect
Arthroplasty Today 2 (2016) 77e82Contents lists avaiArthroplasty Today
journal homepage: http: / /www.arthroplastytoday.org/Original researchEffects of tranexamic acid and bipolar sealer alone or in combination
in primary total knee arthroplasty: a prospective, randomized,
controlled trial
Alexandru Seviciu, MD a, *, Irwin Gross, MD b, Samreen Fathima, MPH c,
Stephen M. Walsh, MD d, e
a Department of Anesthesia, Eastern Maine Medical Center, Bangor, ME, USA
b Transfusion Services, Eastern Maine Medical Center, Bangor, ME, USA
c Clinical Research Center, Eastern Maine Medical Center, Bangor, ME, USA
d Department of Orthopedics, Eastern Maine Medical Center, Bangor, ME, USA
e Down East Orthopedics, Bangor, ME, USAa r t i c l e i n f o
Article history:
Received 16 October 2015
Received in revised form
28 December 2015
Accepted 31 December 2015
Available online 31 March 2016
Keywords:
Tranexamic acid
Blood loss
Total knee arthroplasty
Bipolar sealer system
Hemoglobin changeNo author associated with this paper has disclose
conﬂicts which may be perceived to have impending
full disclosure statements refer to http://dx.doi.org/10
Clinicaltrials.gov registration no.: NCT02374398.
* Corresponding author. 489 State St, Bangor, ME
973 5918.
E-mail address: aseviciu@emhs.org
http://dx.doi.org/10.1016/j.artd.2015.12.007
2352-3441/Copyright © 2016 The Authors. Published b
BY-NC-ND license (http://creativecommons.org/licensa b s t r a c t
Background: The purpose of this study was to compare 2 blood management interventions, tranexamic
acid (TXA) and bipolar sealer system (BSS) used independently or in combination with a control group
during primary total knee arthroplasty (TKA).
Methods: A total of 127 TKA patients were enrolled and randomized into 4 groups: Intravenous TXA plus
the BSS (N ¼ 29, group 1); TXA only (N ¼ 29, group 2); BSS only (N ¼ 31, group 3); and intravenous
normal saline as a control group (N ¼ 32, group 4).
Results: Changes in hemoglobin from baseline to postoperative follow-up were signiﬁcantly lower
among patients who received TXA plus BSS and those receiving TXA only when compared with the
control. BSS only did not differ signiﬁcantly when compared to the control group. In addition, TXA plus
BSS was as efﬁcacious as TXA only in preserving postoperative hemoglobin.
Conclusions: In other terms, using bipolar sealer did not add to the effect of TXA in reducing the post-
operative hemoglobin drop in primary TKA.
Copyright © 2016 The Authors. Published by Elsevier Inc. on behalf of American Association of Hip and
Knee Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
Total knee arthroplasty (TKA) is associated with signiﬁcant
blood loss, subsequent anemia, and the periodic need for intra-
operative or postoperative blood transfusions [1,2]. The anemia
could lead to unwanted hemodynamic changes in patients with
underlying medical conditions such as coronary artery disease or
valvular disease and may have a negative impact for patients’
functional recovery during rehabilitation [3].d any potential or pertinent
conﬂict with this work. For
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, 04401, USA. Tel.: þ1 207
y Elsevier Inc. on behalf of Americ
es/by-nc-nd/4.0/).Likelihood of transfusion in total joint arthroplasty is largely
dependent on 4 factors: (1) baseline hemoglobin (Hb) and he-
matocrit before surgery; (2) surgical blood loss (volume); (3) the
“transfusion trigger,” that is, Hb level belowwhich the surgeon and/
or anesthesiologist are likely to make a decision to transfuse; and
(4) body size and hence total blood volume. Considering the po-
tential risks of blood transfusion [4,5], various preoperative, intra-
operative, and postoperativemethods have been used to reduce the
amount of bleeding associated with surgery. These methods
include administration of erythropoietin, autologous blood dona-
tion and retransfusion, intraoperative red cell salvage, acute nor-
movolemic hemodilution, controlled hypotension, meticulous
operative technique, and use of antiﬁbrinolytic drugs. In terms of
reducing surgical blood loss, success has been achieved with
intraoperative use of different drugs and cautery systems.
Tranexamic acid (TXA) is an antiﬁbrinolytic agent that blocks
the conversion of plasminogen to plasmin on the surface of ﬁbrin
and consequently inhibits ﬁbrinolysis. Intravenous TXA has beenan Association of Hip and Knee Surgeons. This is an open access article under the CC
A. Seviciu et al. / Arthroplasty Today 2 (2016) 77e8278successfully used in joint arthroplasty. TKA is usually performed
using a tourniquet, which offers better visibility of the surgical site
and reduces intraoperative blood loss; on the other hand, the
tourniquet may activate ﬁbrinolysis. Under those circumstances,
the use of TXA should contribute to reduction of intraoperative and
postoperative blood loss. Overall various studies have shown that
TXA is effective in reducing blood loss and transfusion re-
quirements for TKA [6-12] and does not increase the risk of
thromboembolic complications such as deep vein thrombosis
(DVT), pulmonary embolism (PE), cerebral vascular accident (CVA),
or myocardial infarction [9].
Another important method of reducing perioperative blood loss
for TKA is represented by surgical hemostasis. Standard electro-
cautery, which uses monopolar radiofrequency energy, is the most
common method used to obtain intraoperative hemostasis. How-
ever, monopolar electrocautery is associated with local tissue
damage from charring and a greater risk of postoperative bleeding
and anemia [13]. The bipolar sealer system (BSS) works at a mo-
lecular level by heat-driven transformation of the collagen triple
helix structure. Local temperatures under 100C are sufﬁcient toFigure 1. Study enrollment ﬂow diagram. Both: TXA plus BSS (group 1); IV (TXA): TXAshrink collagen ﬁbers in the walls of blood vessels, effectively
sealing the blood vessels. The device can be used to coagulate
vessels that are actively bleeding or to cauterize tissue surfaces to
prevent bleeding or treat active oozing. The result is a reduction of
the bleeding from both soft tissue and bone. In addition, because of
its mechanism of action, the bipolar sealer, as opposed to the
standard electrocautery, will not char, burn tissue, or produce
smoke. The saline-coupled bipolar sealing has been used success-
fully for other types of orthopaedic surgeries including hip and
spine procedures. Several studies have shown that, compared with
standard electrocautery, the additional use of saline-coupled bi-
polar sealer technology results in reduced blood loss and rates of
transfusion and less decrease of the postoperative Hb from the
preoperative level [13-18].
Themechanisms of action of TXA and bipolar sealer as described
previously are very different. One is a drug, whereas the other is a
device, but use of both is aimed at minimizing blood loss and
improving outcomes after surgery. Although TXA and the bipolar
sealer were shown to be effective in preserving postoperative Hb
independently, there is a signiﬁcant gap in the literature justifyingonly (group 2); local: Aquamantys: BSS only (group 3); placebo: control (group 4).
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ical beneﬁts of bipolar sealer such as reduced pain and swelling are
unsupported and the costs associated with the procedure are high,
further evaluation of the BSS in primary TKA was necessitated.
In this study, our objective was to determine how TXA, bipolar
sealer, both in combination, and control compare in terms of
conserving Hb, reducing total blood loss, length of stay, operating
time, and complications after primary TKA.Material and methods
The study was approved by Eastern Maine Medical Center’s
(EMMC) institutional review board (IRB). All patients were enrolled
after informed consent was obtained. Enrollment was completely
voluntary. To ensure safety, data on complications and adverse
reactions were recorded and reported to the IRB.Participants
Between April 2011 and November 2014, 127 patients under-
going voluntary primary TKA consented to participate in this IRB-
approved trial (Fig. 1). Five patients with missing laboratory data
were excluded from the study. One patient was disqualiﬁed from
participation because of a change from cemented to uncemented
implant. Preoperative teaching and perioperative management
were the same for patients in all groups. Patients over 18 years of
age undergoing elective total primary knee arthroplasty, under
spinal anesthesia, were included in the study. Patients with adverse
reaction to TXA; congenital or acquired coagulation disorder; pre-
operative platelet count <100,000/mL or international normalized
ratio >1.4; history of DVT, PE, or CVA; acquired defective color
vision; renal insufﬁciency (glomerular ﬁltration rate <20 mL/min);
severe liver disease; coronary stents; or pregnant patients were
excluded from the study. All enrolled patients were informed of the
goals of this trial, which were to reduce intraoperative and post-
operative blood loss and transfusion rate, length of stay, surgery
time, and complications.Trial design and setting
This was a randomized double-blind placebo-controlled study
of 127 TKA patients conducted at EMMC in Bangor, Maine. The only
exception to blinding was represented by the surgeon, who could
not be blinded to using the BSS. Enrolled subjects were assigned to
one of 4 groups (Table 1) by block randomization of alternating 4, 8,
and 12 patients per block. All study subjects received standard
electrocautery. Intervention subjects received an intravenous (IV)
bolus of TXA, the BSS (Aquamantys, Medtronic, Minneapolis, MN),
or both. Blinding the interventions and randomly varying the block
size helped reduce the problem of predictability of the sequence.
An equal allocation ratio of 1:1:1:1 was predetermined for each
group at the commencement of the trial. The PharmacyTable 1
Treatment and control group composition.
Group/treatment Group 1 Group 2 Group 3 Group 4
TXA ± BSS TXA only BSS only Control
Intravenous TXA (20 mg/kg) ✓ ✓
Intravenous saline (0.9%) ✓ ✓
BSS ✓ ✓
Standard electrocautery ✓ ✓ ✓ ✓Department at EMMC provided the IV placebo or the IV TXA ac-
cording to the randomization process.
Drug and device
As per the clinical recommendations by the medical advisory
panel published in December 2014 [19], doses of intravenous TXA
in orthopaedic surgery varied greatly. In a systematic review of
randomized controlled trials by Kagoma et al. [20], 21 trials showed
prescribing a dose of TXA ranging from a 10- to 20-mg initial bolus
followed either by an infusion of 1-10 mg/kg/h for 4-30 hours or
repeated doses of the initial dose of TXA every 3 hours for 1 to 4
doses. In TKA, an intraoperative dose of 10 mg/kg initial bolus of
TXA followed by a second similar dose at 3 hours is most common.
Literature suggests a dose of 20 mg/kg of TXA is suitable for TKA
[21,22]. Owing to the drug’s prolonged extravascular effectiveness,
we decided to use one 20 mg/kg intravenous dose of TXA which
was given as a bolus over 20 minutes starting at the beginning of
surgery (skin incision) to all patients in groups 1 and 2 (TXA plus
the BSS and TXA only, respectively). We chose to administer the
drug after tourniquet inﬂation and skin incision so as to allow
enough time to address the potential drop in blood pressure and
correct it before IV TXA bolus administration. Clinical recommen-
dations suggest that therapeutic level for TXA can be maintained
for approximately 8 hours after surgery [19].
The BSS is Food and Drug Administration approvedwith surgical
indications that include TKA and was used by the orthopaedic
surgeon in patients in groups 1 and 3 (TXA plus the BSS and bipolar
system only, respectively).
All surgeries were performed by one surgeon under spinal
anesthesia with a femoral nerve block. A tourniquet was used at
250 mmHg, inﬂated at the time of incision and let down before
closing. All knees were a cemented, cruciate-retaining design
(Zimmer NexGen, Warsaw, IN). A mini-midvastus approach was
used with meticulous hemostasis in all cases. The bipolar sealer
was used in a standard fashion “painting” the posterior capsule and
synoviumwith care in an attempt to seal all of the available surface
area. No postoperative drains were used and patients were mobi-
lized on the day of surgery.
Outcome measures
The change in Hb at day 3 was chosen as the primary end
point. About 33% of the patients were missing Hb data on day 3
because of early discharge. To reduce the attrition bias, we decided
to replace missing Hb values on day 3 with Hb values taken on day
2. The decision to study Hb change as the primary end point was
made looking at our previous success in reducing and nearly
eliminating transfusions via our preoperative anemia manage-
ment program. Our institution’s transfusion trigger threshold as a
part of the patient blood management program is between 7 and 8
g/dL of Hb in stable medical or surgical patients. It is worth noting
that the mean transfusion rate at our institution for primary TKAs
over a 5-year period (2010-2014) after the implementation of the
patient blood management program in 2009 was 4.04%
(Supplementary Table 1), and the average transfusion rate of our
lead surgeonwas zero. Secondary end points for the 4 groups were
transfusion rates and total packed red blood cells transfusion or
units administered (if any), length of stay, surgery time, compli-
cations such as DVT, PE, myocardial infarction, CVA, and estimated
blood loss (EBL).
The EBL was determined with the Gross formula [23]. According
to a review article published in 2013, Gross’s formula although
developed in 1983 is still widely used as reported [24]. The formula
which is relatively easy to use is described as follows:
Table 3
One-way analysis of variance results for primary and secondary outcomes.
A. Seviciu et al. / Arthroplasty Today 2 (2016) 77e8280Patient blood volumeðPBVÞ ¼ Kð1Þ  heightðmÞ3 þ Kð2ÞVariable Group 1 Group 2 Group 3 Group 4 P value
TXA þ BSS TXA only BSS only Control
Change in
Hb (g/dL)
2.6 ± 1.0 2.6 ± 0.9 3.2 ± 1.1 3.7 ± 1.1 .0002a
Change in
Ht (%)
6.8 ± 2.58 7.1± 2.51 8.6 ± 3.22 10.0 ± 3.38 .00008a
EBL (mL) 746.6 ± 270 747.9 ± 298 938.9 ± 376 1077.6± 371 .0002a
Hospital
stay (d)
2.6 ± 0.77 2.9 ± 0.88 2.5 ± 0.56 2.6 ± 0.47 .208
Operating
time (min)
92.7 ± 12.5 87.2 ± 10.1 90.6 ± 11.8 89.1 ± 11.6 .312
Ht, hematocrit.
The data are reported as mean ± standard deviation.weightðkgÞ þ Kð3Þ;
where K(1) ¼ 0.3669 (male), 0.3561 (female); K(2) ¼ 0.03219
(male), 0.03308 (female); and K(3) ¼ 0.6041 (male), 0.1833
(female).
Estimated blood loss ¼ PBV
h
Hematocritinitial
Hematocritfinal
i.
Hematocritmean;
where mean hematocrit is the sum of initial and ﬁnal hematocrit
divided by 2.a One-way analysis of variance P values are signiﬁcant at P < .05.Statistical methods
Comparisons between the 4 groups were made using a 1-way
analysis of variance and Fisher’s least signiﬁcant difference post
hoc test for continuous variables, and Pearson’s chi-square test for
categorical variables. Normality was assessed using the Shapiro-
Wilk test; variance homogeneity was assessed using the Levene's
test of homogeneity of variances. All analyses were carried out
using SPSS version 21, and statistical signiﬁcancewas accepted for P
values <.05. Sample size calculations were determined with the
software nQuery using a 1-way of analysis design with 4 groups.
Assumptions were that the standard deviation of change for all
groups would be 1.3 g/dL and that the control group (group 4)
would have an average Hb loss of 3.5 g/dL, the bipolar sealer group
(group 3) a loss of 3.0 g/dL, the TXA group (group 2) a loss of
2.5 g/dL, and for the combination group (group 1), we assumed the
most conservative result for sample size calculations, a loss of
3.0 g/dL. The average loss value and standard deviation came from
averaging results of past studies [12,25]. A sample size of 35 sub-
jects per group provided 80% power to detect the differences
described previously.Results
A total of 127 patients were enrolled, and 121 had complete data
for analysis (29 in group 1; 29 in group 2; 31 in group 3, and 32 in
group 4). There were no signiﬁcant demographic differences
among the 4 groups (Table 2). Descriptive data for each of the 4
groups are shown in Table 2. Data are presented asmean± standard
deviation. Compared to the preoperative Hb level, postoperative Hb
decreased by 2.6 ± 1, 2.6 ± 0.9, 3.2 ± 1.1, and 3.7 ± 1.1 mg/dL in
groups 1, 2, 3, and 4, respectively, and the differences between
these treatment groups were statistically signiﬁcant, F(3,117) ¼
7.088, P ¼ .0002 (Table 3). Least signiﬁcant difference analysisTable 2
Participant characteristics.
Characteristic Group 1 Group 2
N ¼ 29 N ¼ 29
Age (y) 61.1 ± 10.5 65.7 ± 8.6
Gender (F:M) 16:13 13:14
BMI (kg/m2) 33.76 ± 7.8 32.31 ± 7.20
Height (m) 1.7 ± 0.07 1.69 ± 0.08
Weight (kg) 98.4 ± 25.6 92.5 ± 25.9
Preop Hb (g/dL) 13.92 ± 1.22 14 ± 1.10
Preop Ht (%) 41.1 ± 3.28 41.7 ± 3.20
F, female; Ht, hematocrit; M, male.
The data are reported as mean ± standard deviation.
Group 1: TXA plus BSS; group 2: TXA only; group 3: BSS only; group 4: control.revealed that both TXA groups (groups 1 and 2) scored a statisti-
cally signiﬁcantly lower drop in Hb than the control (group 4; P <
.05). Bipolar sealer (group 3) did not differ signiﬁcantly from the
control. Within the TXA groups, our study could not detect a dif-
ference between groups 1 and 2 (Table 4). Findings were corrobo-
rated in the secondary outcomes of change in hematocrit and EBL.
Hospital stay and operating time did not differ statistically between
the groups (Table 3). There were no red blood cell transfusions,
complications, or adverse events reported intraoperatively or
postoperatively. Analysis of the cost data indicated mean total
direct cost of the procedure to be higher in the bipolar sealer group
than in the TXA group. However, the total direct cost per case dif-
ference was not statistically signiﬁcant between the groups.
Discussion
The results of our trial indicate that TXA alone is as efﬁcacious as
TXA plus the BSS in preserving postoperative Hb. In other terms,
use of bipolar sealer did not enhance the effects of TXA in
improving outcomes of primary TKA.
A review published in 2014 by Saltzman et al. [13] listed 4
randomized controlled trials and 1 case control study which
demonstrated that BSS is not superior over standard electrocautery.
Two of the ﬁve studies were in TKA [26,27] and 3 were in total hip
arthroplasty [16,17,28]. Outcome measures of drain output, post-
operative Hb drop, transfusions, length of stay, and surgery time
were studied. A meta-analysis by Yang et al. [29] also reported that
bipolar sealer is not superior to standard electrocautery in primary
hip arthroplasty.
Our institution’s total direct cost of using bipolar sealer and TXA
in combination is 15 times higher than the cost of using TXA alone
in primary TKA. This rise in cost for this step in the procedure did
not translatewell into a rise in overall direct cost per case. AlthoughGroup 3 Group 4 Total
N ¼ 31 N ¼ 32 N ¼ 121
64.8 ± 8.0 62.9 ± 8.4 63.6 ± 8.9
17:14 18:14 64:55
31.58 ± 6.4 32.23 ± 6.4 32.4 ± 6.9
1.69 ± 0.08 1.66 ± 0.09 1.69 ± 0.08
90.6 ± 20.4 89.4 ± 17.9 92.9 ± 22.6
13.85 ± 1.16 13.99 ± 1.32 13.9 ± 1.20
41.1 ± 3.09 41.4 ± 3.85 41.3 ± 3.36
Table 4
Post hoc group comparisons of mean Hb change.
Treatment
group (A)
Treatment
group (B)
Mean difference
in Hb (A  B)
SE P value CI (L-U)
Group 1 Group 2 0.02 0.27 .940 0.56 to 0.52
Group 1 Group 3 0.57a 0.27 .035 1.11 to 0.04
Group 1 Group 4 1.05a 0.27 .0001 1.58 to 0.52
Group 2 Group 3 0.55a 0.27 .042 1.09 to 0.02
Group 2 Group 4 1.03a 0.27 .0002 1.56 to 0.50
Group 3 Group 4 0.47 0.26 .074 1.00 to 0.05
CI (L-U), conﬁdence interval (lower-upper); SE, standard error.
Group 1: TXA plus BSS; group 2: TXA only; group 3: BSS only; group 4: control.
a Least squared difference test P values are signiﬁcant at .05.
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group 2 > group 4), the cost per case difference is not signiﬁcant
statistically. There are several direct hospital and patient charac-
teristics and indirect physician preferences which should be
considered while estimating overall cost per case. Therefore, a
comprehensive cost-effectiveness analysis can help us better un-
derstand the individual procedural impacts on overall costs. Our
TXA dosing regimen might decrease the costs associated with
administering TXA, but its effect on the cost difference with bipolar
sealer would be negligible as TXA is a relatively inexpensive drug.
Considering the cost difference between the IV TXA and the BSS
and based on our ﬁndings from the present study, our team’s
practice has decided to stop the use of bipolar sealer for primary
TKAs. It will be of interest to see how our current change in practice
can impact procedural costs in future. Morris et al. [17] also re-
ported that their teams’ practice has stopped using bipolar sealer
for total hip arthroplasty. They found in their randomized trial that
bipolar sealer use did not improve hemostasis but increased the
costs several times compared to standard electrocautery. Never-
theless, we recommend speciﬁc cost-effectiveness studies before
implementing our ﬁndings. We anticipate that the results of such
studies may be different depending on the patient- and surgeon-
related factors.
None of the patients in our study suffered complications related
to administration of TXA, electrosurgery, or arthroplasty in general.
Nonetheless, further research will be required to add to the safety
proﬁle of the device and assess long-term effects of not using the
bipolar sealer. Also, patient-speciﬁc conditions such as vascular
abnormalities or elevated bleeding risks should be studied in terms
of bipolar sealer use to assess its signiﬁcance in these patients.
Although our study results showed no signiﬁcant postoperative Hb
reduction in the BSS group compared to the control, other studies
have found BSS to be better than the control [14,15]. As suggested in
a review by Saltzman et al. [13], complex revision cases, patients
with coagulation defects, might experience some beneﬁt using this
technology.
Limitations of our study are as follows: (1) All surgeries were
conducted by one physician at one hospital; hence, ﬁndings might
be different in other settings hence less generalizability. (2) Because
we used a block randomization design and did not enroll the
planned number of 35 subjects in each group, sample sizes are
similar but not equal within each group. In spite of this, power was
not compromised as the mean Hb loss was higher with lower
standard deviations than what was assumed for power calcula-
tions. (3) Our study had no transfusion patients because transfusion
rates for primary total knees performed were zero during the study
period. This could be due to the successful overall approach to
primary TKA cases at our institution, including timely preoperative
anemia screening and optimization of day of surgery Hb, anesthesia
techniques, methodical surgical hemostasis, and a conservative
transfusion threshold. Success with the transfusions at ourinstitution was published previously [30]. These changes were in
place before the onset of the present study and directed our pri-
mary outcome to be change in Hb given the success of our existing
program at eliminating transfusions. (4) Hb at day 3 was our pri-
mary end point. About 33% of the enrolled patients were missing
Hb values on day 3 because of early discharge. To reduce attrition
bias, we replaced the missing Hb values on day 3 with Hb values on
day 2 causing smaller follow-up times in 33% of patients. We un-
derstand that this procedure might be seen as underreporting of
the Hb drop. Data are presented in Supplementary Table 2. Intra-
operative bleeding, cost data, and functional outcomes such as pain,
rehabilitation were not assessed. These are important variables but
were not the focus of this study.
Overall, although our study had several limitations, it is a high-
quality randomized controlled trial with good homogeneity. Our
study adds to the current knowledge about the use of bipolar
sealers and can help inform long-term organizational decisions. It
also makes considerable connections to previous research in this
important area and provides insight for further research that can
put emphasis on using or not using bipolar sealers.Conclusions
In conclusion, our study showed that the mean Hb drop from
baseline to postoperative day 2 or 3 was signiﬁcantly lower in the
TXA alone and TXA-plus-BSS groups than in the control group. In
addition, TXA alonewas as efﬁcacious as TXA plus the bipolar sealer
system in preserving postoperative Hb. The hospital stay and
operating time were not statistically different among the 4 groups.Acknowledgments
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